Heike Keilhack

6.9k total citations · 2 hit papers
47 papers, 3.2k citations indexed

About

Heike Keilhack is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Heike Keilhack has authored 47 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Immunology. Recurrent topics in Heike Keilhack's work include Cancer-related gene regulation (19 papers), Epigenetics and DNA Methylation (15 papers) and Chromatin Remodeling and Cancer (12 papers). Heike Keilhack is often cited by papers focused on Cancer-related gene regulation (19 papers), Epigenetics and DNA Methylation (15 papers) and Chromatin Remodeling and Cancer (12 papers). Heike Keilhack collaborates with scholars based in United States, Germany and Japan. Heike Keilhack's co-authors include Robert A. Copeland, Sarah K. Knutson, Tim J. Wigle, Frank‐D. Böhmer, Kevin W. Kuntz, Mikel P. Moyer, Richard Chesworth, Benjamin G. Neel, Victoria M. Richon and Margaret Porter Scott and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Heike Keilhack

46 papers receiving 3.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. profile →
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Scott Ribich, Heike Keilhack et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Heike Keilhack	2.7k	623	608	424	262	47	3.2k
Suzanne Schubbert	1.7k 0.6×	736 1.2×	540 0.9×	208 0.5×	223 0.9×	22	2.3k
Keith Orford	1.9k 0.7×	938 1.5×	264 0.4×	325 0.8×	446 1.7×	36	2.7k
Richard Kendall	1.8k 0.7×	837 1.3×	324 0.5×	238 0.6×	476 1.8×	43	3.0k
Matthew R. Janes	2.2k 0.8×	594 1.0×	285 0.5×	195 0.5×	273 1.0×	26	2.7k
Ayana Sawai	2.7k 1.0×	1.1k 1.8×	238 0.4×	354 0.8×	335 1.3×	10	3.3k
Pingda Ren	2.3k 0.8×	570 0.9×	291 0.5×	176 0.4×	246 0.9×	49	3.2k
Kim H.T. Paraiso	1.9k 0.7×	954 1.5×	589 1.0×	203 0.5×	368 1.4×	28	2.5k
Nathalie Dhomen	2.2k 0.8×	1.6k 2.6×	474 0.8×	375 0.9×	585 2.2×	34	3.2k
Vanessa Rodrik-Outmezguine	2.1k 0.8×	943 1.5×	200 0.3×	367 0.9×	458 1.7×	32	2.8k
Narsis Attar	2.1k 0.8×	1.3k 2.1×	297 0.5×	298 0.7×	277 1.1×	13	2.6k

Countries citing papers authored by Heike Keilhack

Since Specialization

Citations

This map shows the geographic impact of Heike Keilhack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Keilhack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Keilhack more than expected).

Fields of papers citing papers by Heike Keilhack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Keilhack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Keilhack. The network helps show where Heike Keilhack may publish in the future.

Co-authorship network of co-authors of Heike Keilhack

This figure shows the co-authorship network connecting the top 25 collaborators of Heike Keilhack. A scholar is included among the top collaborators of Heike Keilhack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heike Keilhack. Heike Keilhack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Kevin W., Laurie B. Schenkel, Kerren K. Swinger, et al.. (2022). Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response. ImmunoHorizons. 6(7). 432–446. 8 indexed citations

Wigle, Tim J., Laurie B. Schenkel, Yue Ren, et al.. (2020). In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement. Cell chemical biology. 27(7). 877–887.e14. 17 indexed citations

Lu, Alvin, Ryan Abo, Yue Ren, et al.. (2019). Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation. Biochemical Pharmacology. 167. 97–106. 39 indexed citations

Drew, Allison E., Trupti Lingaraj, Natalie M. Warholic, et al.. (2017). EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. Molecular Cancer Therapeutics. 16(11). 2586–2597. 52 indexed citations

Chan-Penebre, Elayne, Kelli Armstrong, Allison E. Drew, et al.. (2017). Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Molecular Cancer Therapeutics. 16(5). 850–860. 127 indexed citations

Keilhack, Heike & Paul Chang. (2017). In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells. Methods in molecular biology. 1608. 321–336. 2 indexed citations

Kawano, Satoshi, Alexandra Grassian, Masumi Tsuda, et al.. (2016). Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE. 11(7). e0158888–e0158888. 58 indexed citations

Grassian, Alexandra, Sarah K. Knutson, Kevin W. Kuntz, et al.. (2015). A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality. Biological Procedures Online. 17(1). 15–15. 5 indexed citations

Knutson, Sarah K., Natalie M. Warholic, L. Danielle Johnston, et al.. (2014). Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE. 9(12). e111840–e111840. 55 indexed citations

10.

Keilhack, Heike. (2013). Preclinical Characterization of E7438, a Potent, Selective EZH2 Inhibitor with Robust Antitumor Activity Against EZH2 Mutated NHL Xenografts in Mice. Annals of Oncology. 24. i7–i7. 3 indexed citations

11.

Majer, Christina R., Lei Jin, Margaret Porter Scott, et al.. (2012). A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients. FEBS Letters. 586(19). 3448–3451. 116 indexed citations

12.

Matsuo, Kosuke, Ahmed Bettaieb, Naoto Nagata, et al.. (2011). Regulation of Brown Fat Adipogenesis by Protein Tyrosine Phosphatase 1B. PLoS ONE. 6(1). e16446–e16446. 35 indexed citations

13.

Bettaieb, Ahmed, Siming Liu, Yannan Xi, et al.. (2011). Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase. Journal of Biological Chemistry. 286(11). 9225–9235. 54 indexed citations

14.

Kubota, Kazuishi, Rana Anjum, Yonghao Yu, et al.. (2009). Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nature Biotechnology. 27(10). 933–940. 89 indexed citations

15.

Martini, Paolo, Deanne Taylor, Jadwiga Biénkowska, et al.. (2008). Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients. The Journal of Steroid Biochemistry and Molecular Biology. 109(3-5). 207–211. 3 indexed citations

16.

Keilhack, Heike, Frank David, Malcolm J. McGregor, Lewis C. Cantley, & Benjamin G. Neel. (2005). Diverse Biochemical Properties of Shp2 Mutants. Journal of Biological Chemistry. 280(35). 30984–30993. 229 indexed citations

17.

Anastasiadis, Panos Z., et al.. (2001). Identification of Src Phosphorylation Sites in the Catenin p120. Journal of Biological Chemistry. 276(30). 28006–28013. 124 indexed citations

18.

Keilhack, Heike, Ulf Hellman, Jolanda van Hengel, et al.. (2000). The Protein-tyrosine Phosphatase SHP-1 Binds to and Dephosphorylates p120 Catenin. Journal of Biological Chemistry. 275(34). 26376–26384. 55 indexed citations

19.

Keilhack, Heike, Tencho Tenev, Jasminka Godovac‐Zimmermann, et al.. (1998). Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling. Journal of Biological Chemistry. 273(38). 24839–24846. 127 indexed citations

20.

Tenev, Tencho, Heike Keilhack, Siniša Tomić, et al.. (1997). Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera. Journal of Biological Chemistry. 272(9). 5966–5973. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact